Puttkammer M, Gaertner H J, Mahal A, May J, Binz U, Heimann H
Universitäts-Nervenklinik Tübingen.
Arzneimittelforschung. 1987 Jun;37(6):721-5.
The hypothesis that the phenoxypropanolamine derivative CGP 361 A possesses anxiolytic activity was examined in 80 female healthy volunteers. Each volunteer received the treatment under double-blind conditions as part of a 1-way analysis of variance design. The medication factor had 4 levels (CGP 361 A, propranolol, diazepam and placebo). Stress was induced by asking subjects to deliver a free speech in front of a video camera. The anxiety was measured using adjectives list, state-trait-anxiety inventory and visual analogue scales. The physiological equivalents observed were pulse rate and skin resistance. The results support the hypothesis that a single dose of 10 mg CGP 361 A has a higher anxiolytic effect than 10 mg propranolol, 5 mg diazepam and placebo, with the peripheral beta-blocking effects (established by pulse rate) being no stronger than with propranolol. No subjective or objective sedation has been determined under the different drug conditions.
在80名健康女性志愿者中检验了苯氧丙醇胺衍生物CGP 361 A具有抗焦虑活性这一假说。作为单向方差分析设计的一部分，每位志愿者在双盲条件下接受治疗。药物因素有4个水平（CGP 361 A、普萘洛尔、地西泮和安慰剂）。通过要求受试者在摄像机前进行自由演讲来诱发应激。使用形容词列表、状态-特质焦虑量表和视觉模拟量表来测量焦虑。观察到的生理等效指标是脉搏率和皮肤电阻。结果支持了以下假说：单剂量10 mg CGP 361 A比10 mg普萘洛尔、5 mg地西泮和安慰剂具有更高的抗焦虑作用，其外周β受体阻断作用（通过脉搏率确定）不比普萘洛尔更强。在不同药物条件下未发现主观或客观的镇静作用。
